Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KPTI NASDAQ:KZIA NASDAQ:RANI NASDAQ:SCYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKPTIKaryopharm Therapeutics$5.59-5.6%$4.35$3.51▼$16.95$48.47M0.28126,652 shs124,649 shsKZIANovogen$7.42-7.6%$8.43$2.86▼$39.05$7.49M2.64589,235 shs31,930 shsRANIRani Therapeutics$0.55+0.7%$0.53$0.39▼$3.75$39.80M-0.021.19 million shs698,631 shsSCYXSCYNEXIS$0.80-4.5%$0.76$0.66▼$1.79$33.65M1.64170,420 shs43,740 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKPTIKaryopharm Therapeutics0.00%+50.25%+53.77%+15.40%-51.77%KZIANovogen0.00%-1.11%-20.89%+120.60%-59.85%RANIRani Therapeutics0.00%+4.17%+32.34%-21.43%-80.29%SCYXSCYNEXIS0.00%-2.90%+15.85%+0.95%-51.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationKPTIKaryopharm Therapeutics3.8431 of 5 stars3.40.00.04.62.32.50.6KZIANovogen3.9688 of 5 stars3.85.00.00.03.00.00.0RANIRani Therapeutics3.179 of 5 stars3.55.00.00.02.11.70.6SCYXSCYNEXIS1.3854 of 5 stars0.05.00.00.02.70.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKPTIKaryopharm Therapeutics 2.80Moderate Buy$34.00508.23% UpsideKZIANovogen 3.50Strong Buy$14.0088.68% UpsideRANIRani Therapeutics 3.00Buy$7.331,224.18% UpsideSCYXSCYNEXIS 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest KZIA, SCYX, RANI, and KPTI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/12/2025KPTIKaryopharm TherapeuticsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$42.00 ➝ $25.007/16/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeBuy ➝ Neutral7/11/2025KPTIKaryopharm TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$27.007/10/2025KZIANovogenHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeBuy ➝ Strong-Buy$13.006/11/2025KZIANovogenMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00(Data available from 8/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKPTIKaryopharm Therapeutics$145.24M0.33N/AN/A($22.10) per share-0.25KZIANovogen$1.51M4.96N/AN/A($9.87) per share-0.75RANIRani Therapeutics$1.03M38.64N/AN/A$0.06 per share9.23SCYXSCYNEXIS$3.26M10.33N/AN/A$1.45 per share0.55Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKPTIKaryopharm Therapeutics-$76.42M-$14.59N/AN/AN/A-90.02%N/A-84.28%11/4/2025 (Estimated)KZIANovogen-$17.56MN/A0.00∞N/AN/AN/AN/AN/ARANIRani Therapeutics-$30.02M-$0.91N/AN/AN/AN/A-1,258.76%-97.97%N/ASCYXSCYNEXIS-$21.29M-$0.40N/A16.05N/A-599.05%-43.04%-28.21%11/5/2025 (Estimated)Latest KZIA, SCYX, RANI, and KPTI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025SCYXSCYNEXIS-$0.23-$0.14+$0.09-$0.14$0.15 million$1.36 million8/11/2025Q2 2025KPTIKaryopharm Therapeutics-$3.80-$4.32-$0.52-$4.32$37.92 million$37.93 million8/7/2025Q2 2025RANIRani Therapeutics-$0.19-$0.18+$0.01-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKPTIKaryopharm TherapeuticsN/AN/AN/AN/AN/AKZIANovogenN/AN/AN/AN/AN/ARANIRani TherapeuticsN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKPTIKaryopharm TherapeuticsN/A0.990.94KZIANovogenN/A0.21N/ARANIRani Therapeutics2.750.540.54SCYXSCYNEXISN/A5.205.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKPTIKaryopharm Therapeutics66.44%KZIANovogen30.89%RANIRani Therapeutics30.19%SCYXSCYNEXIS54.37%Insider OwnershipCompanyInsider OwnershipKPTIKaryopharm Therapeutics2.75%KZIANovogen1.00%RANIRani Therapeutics45.08%SCYXSCYNEXIS4.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKPTIKaryopharm Therapeutics3808.67 million8.43 millionOptionableKZIANovogen121.01 million997,000OptionableRANIRani Therapeutics11071.87 million39.47 millionOptionableSCYXSCYNEXIS6041.93 million39.89 millionOptionableKZIA, SCYX, RANI, and KPTI HeadlinesRecent News About These CompaniesScynexis reports Q2 EPS (14c), consensus (19c)August 14, 2025 | msn.comSCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | finanznachrichten.deSCYNEXIS Reports Improved Financials Amidst Strategic DevelopmentsAugust 14, 2025 | msn.comSCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | globenewswire.comSCYNEXIS (SCYX) to Release Quarterly Earnings on ThursdayAugust 13, 2025 | americanbankingnews.comSCYNEXIS Inc. Advances Phase 3 Study for Invasive Candidiasis TreatmentAugust 8, 2025 | msn.comSCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSKMay 30, 2025 | nasdaq.comSCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA HoldMay 28, 2025 | insidermonkey.comSCYNEXIS Resumes Patient Dosing in Phase 3 MARIO StudyMay 28, 2025 | globenewswire.comSCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | finance.yahoo.comScynexis to present preclinical data on SCY-247 at ESCMID MeetingApril 9, 2025 | markets.businessinsider.comSCYNEXIS Full Year 2024 Earnings: Misses ExpectationsMarch 14, 2025 | finance.yahoo.comSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 12, 2025 | markets.businessinsider.comSCYNEXIS, Inc. Advances Phase 1 Trial of SCY-247 Antifungal and Prepares for Phase 3 MARIO Study RestartMarch 12, 2025 | quiverquant.comQSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 12, 2025 | globenewswire.comSCYNEXIS Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal InfectionsDecember 18, 2024 | markets.businessinsider.comMaxim Group Keeps Their Buy Rating on SCYNEXIS (SCYX)December 5, 2024 | markets.businessinsider.comSCYNEXIS’s Strong Financial Position and Strategic Advancements Drive Buy RatingNovember 9, 2024 | markets.businessinsider.comSCYNEXIS Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNovember 6, 2024 | globenewswire.comInvestors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five yearsOctober 30, 2024 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWhy the American Eagle Stock Rally Isn't Just Speculation By Gabriel Osorio-Mazilli | July 28, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Short Squeeze Candidates With Big Catalysts on the HorizonBy Dan Schmidt | July 25, 20253 Stocks Riding the AI Data Center Buildout WaveBy Chris Markoch | August 6, 2025A Huge Bet on Uranium: Why Traders Are Piling Into the URNM ETFBy Jeffrey Neal Johnson | July 24, 2025KZIA, SCYX, RANI, and KPTI Company DescriptionsKaryopharm Therapeutics NASDAQ:KPTI$5.59 -0.33 (-5.57%) Closing price 04:00 PM EasternExtended Trading$5.62 +0.03 (+0.45%) As of 05:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.Novogen NASDAQ:KZIA$7.42 -0.61 (-7.60%) Closing price 03:59 PM EasternExtended Trading$7.61 +0.19 (+2.56%) As of 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.Rani Therapeutics NASDAQ:RANI$0.55 +0.00 (+0.69%) Closing price 04:00 PM EasternExtended Trading$0.54 -0.02 (-3.21%) As of 05:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.SCYNEXIS NASDAQ:SCYX$0.80 -0.04 (-4.45%) Closing price 04:00 PM EasternExtended Trading$0.80 +0.00 (+0.31%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Whirlpool A Screamin’ Buy in 2025? Signs Say Yes Rocket Stock Just Broke Out, But EPS Growth Still Isn't Priced In Buffett Makes Big Moves Outside of UNH: A Buy and Sell Breakdown Applied Materials' Knee-Jerk Sell-Off Is Your Signal to Buy Is Reddit Stock Too Hot, or Just Right? Buffett’s Mystery Buy Revealed, and It’s a Big Bet on UNH AI Glasses to Replace Smartphones? Meta Is Taking Aim at Apple Why Arista's Blowout Q2 Is Good News for Chip-Giant Broadcom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.